Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Biomedical Chromatography : BMC|October 18, 2013
Development and validation of an LC-ESI-MS/MS method for the quantitation of hemslecin A in rhesus monkey plasma and its application in pharmacokineticsMin Bai, Hong-Liang Li, Jian-Chang He, et al.
Plos One|May 20, 2014
Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancerGong-Hao He, Jia-Ji Lin, Wen-Ke Cai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2014
Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancerWen-Ke Cai, Jing Hu, Teng Li, et al.
Drug Development and Industrial Pharmacy|January 20, 2012
Nano-hydroxyapatite/β-tricalcium phosphate ceramics scaffolds loaded with cationic liposomal ceftazidime: preparation, release characteristics in vitro and inhibition to Staphylococcus aureus biofilmsTian-Hua Zhou, Min Su, Bei-Cheng Shang, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|August 30, 2017
The HRH4 rs11662595 mutation is associated with histamine H4 receptor dysfunction and with increased epithelial-to-mesenchymal transition progress in non-small cell lung cancerWen-Ke Cai, Jia-Bin Zhang, Ji-Hui Chen, et al.
International Journal of Nanomedicine|February 15, 2018
Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicityXiao-Qian Dou, Hua Wang, Jing Zhang, et al.
Journal of Drug Targeting|November 8, 2016
IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironmentYu-Jie Liu, Xiao-Qian Dou, Fang Wang, et al.
Frontiers in Immunology|March 18, 2022
Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune ResponseFei Yang, Gui-Li Xu, Jin-Tao Huang, et al.
Pageof 3